A comprehensive assessment of FH patients that combines clinical and molecular data from patients with functional characterization and classification of LDLR variants can elucidate the spectrum of FH phenotypes and provide insight into the development of targeted treatments27. The gene discussed is LDLR; the disease is familial hyperaldosteronism.